What is currently available Three GLP-1 medications matter for the NZ conversation right now: Ozempic (semaglutide, weekly injection), Mounjaro (tirzepatide, a dual GIP/GLP-1 agonist, weekly injection), and Wegovy (the higher-dose semaglutide approved specifically for weight management)
The GH half-life falls by 6%
It is currently one of the most studied next-generation peptides in metabolic research
27747.56 10% OFF Delivery by Today, 11:00 am - 02:00 pm Product Information Description Ingredients Drug Class Dosage Form Uses Dosage In case of Overdose Missed Dose How To Use When Not to Use Side Effects Precautions & Warnings Drug Interactions Food Interactions Storage/Disposal Quick Tips, if any Description The Ozempic pen contains semaglutide , a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the action of the natural hormone GLP-1, crucial for regulating blood sugar levels and appetite
A study on 6,681 people using GLP-1s found that sustained GLP-1 use was associated with a 2.5% absolute risk reduction of myocardial infarction, stroke and cardiovascular mortality over 3.5 years
Potential bad side effects of Ozempic: Gallstones Cholecystitis Thyroid cancer Thyroid tumors Diabetic retinopathy Hypoglycemia Gastroparesis Early reports of adverse side effects mostly involved gallbladder issues
